e-learning
resources
London 2016
Sunday, 04.09.2016
Features and impact of comorbidities in COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
LATE-BREAKING ABSTRACT: Circulating YKL-40 level in COPD patients and their correlations with clinical parameters
Xiaoyue Wang (Nanjing, China), Xiaoyue Wang, Jiadi Chen, Peili Sun, Mao Huang
Source:
International Congress 2016 – Features and impact of comorbidities in COPD
Session:
Features and impact of comorbidities in COPD
Session type:
Thematic Poster
Number:
655
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Xiaoyue Wang (Nanjing, China), Xiaoyue Wang, Jiadi Chen, Peili Sun, Mao Huang. LATE-BREAKING ABSTRACT: Circulating YKL-40 level in COPD patients and their correlations with clinical parameters. Eur Respir J 2016; 48: Suppl. 60, 655
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
LATE-BREAKING ABSTRACT: Tiotropium efficacy and exacerbation risk in patients with different blood eosinophil levels
Source: International Congress 2015 – Emerging strategies for airway disease treatments
Year: 2015
LATE-BREAKING ABSTRACT: Plasma homocysteine is associated with low diffusion capacity (DLCO) in COPD patients
Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura
Year: 2012
LATE-BREAKING ABSTRACT: Cytokines and MMP 9 level in serum and induced sputum of patients with suspicion of occupational COPD
Source: Annual Congress 2012 - Respiratory diseases at at work: epidemiology, inflammation and challenge studies
Year: 2012
LATE-BREAKING ABSTRACT: Biomarkers of tissue turnover are related to annual change in FEV1 in patients with COPD within the ECLIPSE cohort
Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease
Year: 2015
LATE-BREAKING ABSTRACT: The effect of beta2-agonist on lung clearance index in COPD patients
Source: International Congress 2015 – Lung function: new findings and approaches
Year: 2015
LATE-BREAKING ABSTRACT: Elevated cardiovascular risk as measured by QRISK2 score in patients hospitalized for acute COPD exacerbation
versus
stable COPD outpatients
Source: International Congress 2014 – Comorbidities
Year: 2014
Relationship between CRP levels and the severity of COPD acute exacerbations among group D COPD patients.
Source: Virtual Congress 2020 – COPD phenotypes
Year: 2020
Differences in plasma and sputum biomarkers between COPD and COPD-asthma overlap
Source: Annual Congress 2013 –Is it really asthma?
Year: 2013
Circulating copeptin is associated with mortality irrespectively of exacerbation rate in stable COPD
Source: International Congress 2014 – COPD - from biomarkers to novel therapeutic opportunities
Year: 2014
LATE-BREAKING ABSTRACT: Validation of the DECAF score to predict hospital mortality in exacerbations of COPD
Source: International Congress 2015 – COPD: chronic disease and comorbidities
Year: 2015
LATE-BREAKING ABSTRACT: Large differences in rate of reported and unreported COPD exacerbations in Japanese patients; data from the COSMOS-J trial
Source: International Congress 2016 – Clinical characteristics of asthma
Year: 2016
Gender differences in plasma biomarkers levels in patients with COPD
Source: Annual Congress 2010 - Novel markers of lung injury
Year: 2010
Individual variation in the levels of procalcitonin, neopterin, CRP and MR-proANP during a COPD exacerbation and clinical stable state
Source: Annual Congress 2009 - Exacerbations of COPD and bronchiectasis: aetiology and treatment
Year: 2009
LATE-BREAKING ABSTRACT: Plasma MMP-9 is related to a bronchitic COPD phenotype–report from the obstructive lung disease in northern Sweden (OLIN) studies
Source: Annual Congress 2013 –Epidemiology of respiratory disease
Year: 2013
LATE-BREAKING ABSTRACT: Predictive factors of frequent exacerbations in mild grade COPD patients
Source: International Congress 2016 – Managing multimorbidity and lifestyle change in primary care
Year: 2016
LATE-BREAKING ABSTRACT: Exacerbation phenotype directed corticosteroid therapy of COPD: Value of blood eosinophilia (primary results)
Source: International Congress 2015 – The relevance of diagnostic and monitoring tools in clinical practice
Year: 2015
LATE-BREAKING ABSTRACT: Stability of blood eosinophil count in COPD patients in the UK clinical practice research datalink
Source: International Congress 2015 – Treatment and control of respiratory disease
Year: 2015
Inflammatory markers (IL-6, suPAR) and arterial stiffness parameters in COPD patients
Source: International Congress 2016 – Biomarkers and phenotypes of COPD
Year: 2016
LATE-BREAKING ABSTRACT: Biomarkers of ECM turnover and clinical relevant outcomes in COPD: Results of the multicenter PROMISE study
Source: International Congress 2015 – Notable abstracts in COPD: variety
Year: 2015
LATE-BREAKING ABSTRACT: An algorithm for the identification of clinical COPD phenotypes in daily practice
Source: International Congress 2016 – COPD diagnosis and management
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept